The so called 'living drug' Tisagenlecleucel (aka Kymriah™ by Novartis) is a new CAR-T cell therapy = Docs say pricy gene-altering will violently attack, avert, and might cure harsh B-cell leukaemias
Anagram: Julian Lofts
Image: Novartis AG
Image: Novartis AG










![P8207509[1]](https://farm5.staticflickr.com/4394/35897789473_95bb07f5e6.jpg)


